GEISTWERT Rechtsanwälte Lawyers Avvocati

UPC-CFI-629/2026

Establishment Labs S.A. v. GC Aesthetics ParentCo Limited, Nagor Limited, GC Aesthetics Management Limited, GC Aesthetics (Distribution) Limited, GC Aesthetics (France) SAS, EuroSilicone SAS, GC Aesthetics GmbH, GC Aesthetics Spain, S.L.U., Global Consolidated Aesthetics (UK) Limited, GC Aesthetics Holdings Limited, GC Aesthetics Finance Limited, Romed NV

Datum
2026-06-26
Kammer
Brussels (BE) Local Division
Verfahrensart
Counterclaim for revocation
Sprache
EN

Metadaten

Fall-IDUPC-CFI-629-2026-9cd2ee19c3f6
AktenzeichenUPC-CFI-629/2026
RegisterzeichenUPC-CFI-629/2026
Entscheidungsreferenz
Schlagwörter
Leitsätze

Dokumente und Volltext

Textextraktion: pypdf | Seiten: 19

Brussels - Local Division UPC_CFI_1357/2025 UPC_CFI_629/2025 Order II (R.190 RoP) of the Court of First Instance of the Unified Patent Court Issued on 26 June 2026 Concerning EP 3 107 487 B1 HEADNOTES In parallel national and UPC proceedings and based on the circumstances of the case, the UPC should endeavour as much as possible to align the means for obtaining evidence and specifically the submitted requests (in the UK, based on common law, in disclosure proceedings and at the UPC based (i.a.) on R. 190 RoP). Such alignment of requests will lead to a common evidence basis when assessing the infringement action and/or counterclaim for revocation and/or separate invalidity action. This approach is dictated by procedural efficiency and proportionality, balancing the respondent's burden of su ...